Production at Y-Parc in Yverdon-les-Bains

We are building one of the most advanced production facilities in the world in Switzerland and comply with national rules and regulations. MediCrops’ production uses the company’s own design, software and standardised production processes. Our closed cultivation rooms use cutting-edge environmental control technologies to manage all variables, including lighting, temperature, nutrients and water. 

Each of these rooms is sealed with special doors to protect against contamination from air pollutants. Our production process is specifically designed to cultivate standardised cannabis without pesticides. We are also proud of our international quality assurance system with very high hygienic standards, appropriate testing requirements and the strict limitation of pesticides and fungicides.

Show more

MediCrops’ indoor facility for research and manufacturing is being developed at the Y-Parc – one of the most innovative industrial parks in Switzerland.

The Y-Parc in Yverdon creates an  inspiring environment by attracting innovative companies and through its proximity to the University of Lausanne.

With its experienced engineers, MediCrops is constructing an indoor production facility that meets the highest standards. Here, a weekly batch will be produced using standardised and automated processes.

In the new building, clean rooms and pharmaceutical processing facilities are being built on 5,550 m2 of floor space, with the total investment for the first phase of construction amounting to around 30 million Swiss francs. The entire production chain with extraction, distillation, isolation, drying, filling and packaging will take place in the new building. The upper floor will also house an indoor cultivation facility. The end products are extracts, distillates and isolates of the cannabis plant. A new batch can be harvested every week, 52 weeks a year, following a system that we can plan years in advance.

Production process

MediCrops offers its customers premium quality and dependable products based on a highly integrated production process and strict product quality standards. The high vertical integration of the value chain from seed to end product together with independent research and development are the hallmarks of MediCrops’ business model.

Cannabis cultivation

To ensure consistent product quality, cuttings are taken from a parent plant, which then grow into new plants with identical characteristics. This process is known as cloning. The plant is then grown under constantly monitored, consistent conditions before being harvested.  MediCrops  produces a wide range of cultivars to meet the demands of customised patient treatment, including specific cultivar varieties.